Haisco Pharmaceutical Group (002653.SZ): Innovation drug HSK46575 tablet IND application accepted
Hisilicon (002653.SZ) announced that its subsidiary Tibet Hisilicon Pharmaceutical Co., Ltd. will be established in September 2024...
Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Tibet Haisco Pharmaceutical Group Pharmaceuticals Co., Ltd., received an "Acceptance Notice" from the National Medical Products Administration on September 23, 2024. The drug is named HSK46575. HSK46575 is an orally administered, potent, and highly selective small molecule inhibitor developed independently by the company, intended for the treatment of prostate cancer.
Related Articles
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
